Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: A systematic review and meta-analysis of published studies

Oral Oncology

Volumn 50, Issue 11, 2014, Pages 1041-1048

  Petrelli, Fausto ^a   Coinu, Andrea ^a   Riboldi, Valentina ^a   Borgonovo, Karen ^a   Ghilardi, Mara ^a   Cabiddu, Mary ^a   Lonati, Veronica ^a   Sarti, Enrico ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Cetuximab; Chemoradiotherapy; Cisplatin; Head and neck cancer; Locally advanced; Overall survival

Indexed keywords

CETUXIMAB; DOCETAXEL; FLUOROURACIL; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; DISTANT METASTASIS; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK CANCER; HEALTH CARE QUALITY; HUMAN; META ANALYSIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 84928012705     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.08.005     Document Type: Review

References (37)

1. Pignon JP, le MaÎtre A, Maillard E, Bourhis J. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17, 346 patients. Radiother Oncol 2009;92(1):4-14. http://dx.doi.org/10.1016/j.radonc.2009.04.014 [Epub 2009 May 14. PubMed PMID: 19446902].
2. Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol 2011;100(1):33-40.
3. [accessed 25.01.2014].
4. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Longterm results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31(7):845-52.
5. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):21-8;.
6. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):14 [Erratum].
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78.
8. Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J Clin Oncol 2013;31(7):853-9;.
9. Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(13):1702 [Erratum].
10. Tang C, Chan C, Jiang W, Murphy JD, von Eyben R, Colevas AD et al. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head Neck 2014 January 15. http://dx.doi.org/10.1002/hed.23609 [Epub ahead of print].
11. Riaz N, Sherman E, Koutcher L, Shapiro L, Katabi N, Zhang Z et al. Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2014 January 7 [Epub ahead of print].
12. Ley J, Mehan P, Wildes TM, Thorstad W, Gay HA, Michel L, et al. Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma. Oncology 2013;85(5):290-6.
13. Fayette J, Bonnin N, Ferlay C, Lallemant B, Ramade A, Favrel V, et al. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: A study of 157 patients. Anticancer Drugs 2013 Jul;24(6):623-9.
14. Huang J, Baschnagel AM, Chen P, Gustafson G, Jaiyesmi I, Folbe M et al. A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinumbased chemotherapy for locally advanced head neck cancer. Int J Clin Oncol 2013 March 12 [Epub ahead of print].
15. Pajares B, Trigo JM, Toledo MD, Álvarez M, González-Hermoso C, Rueda A, et al. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC Cancer 2013 Jan;18(13): 26.
16. Beijer YJ, Koopman M, Terhaard CH, Braunius WW, van Es RJ, de Graeff A. Outcome and toxicity of radiotherapy combined with chemotherapy or cetuximab for head and neck cancer: our experience in one hundred and twenty-five patients. Clin Otolaryngol 2013 Feb;38(1):69-74.
17. Jensen AD, Krauss J, Weichert W, Bergmann ZP, Freier K, Debus J, et al. Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Radiat Oncol 2011;23(6):122.
18. Caudell JJ, Sawrie SM, Spencer SA, Desmond RA, Carroll WR, Peters GE, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: A comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 2008 Jul 1;71(3):676-81.
19. Al Saleh, Khalid, Safwat, Reham, Bedair, Ahmed et al. Phase II/III randomized study of hyperfractionated radiotherapy with concomitant cetuximab versus concomitant chemotherapy in advanced nonmetastatic head and neck cancer: preliminary report. J Clin Oncol 2012;30(15s) [abstr. e16002].
20. Borchiellini, Delphine, Dupuis, Charlotte, Gal, Jocelyn et al. Induction TPF followed by chemoradiation or radiotherapy-cetuximab in nonresectable advanced head and neck squamous cell carcinoma: A retrospective study in 164 patients. J Clin Oncol 2012;30(15s) [abstr. 16044].
21. Galper SL, Deshpande H, Rose MG et al. Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC). J Clin Oncol 2009;27(15s) [abstr. e17030].
22. Ghi MG, Paccagnella A, Ferrari D et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826). J Clin Oncol 2014;32:5s [abstr. 6004].
23. Peddi P, Shi R, Panu L et al. Cisplatin (CDDP) and radiation versus cetuximab (Cx) and radiation in locally advanced head and neck squamous cell cancer (SCHNC): A retrospective review. J Clin Oncol 2012;30(15s) [abstr. 16009].
24. Grégoire V, Lefebvre JL, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;v184-6(21 Suppl. 5).
25. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802-12.
26. UKCCCR Anal Cancer Trial Working Party and UK Co-ordinating Committee on Cancer Research: Epidermoid anal cancer: Results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:1049-54.
27. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.
28. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349(22):2091-8.
29. Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol 2013;14(3):257-64.
30. Paccagnella A, Ghi MG, Loreggian L, Buffoli A, Koussis H, Mione CA, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: A phase II randomized study. Ann Oncol 2010;21(7):1515-22.
31. Petrelli F, Sarti E, Barni S. Predictive value of human papillomavirus in oropharyngeal carcinoma treated with radiotherapy: An updated systematic review and meta-analysis of 30 trials. Head Neck 2013 Apr 22. http://dx.doi.org/10.1002/hed.23351. [Epub ahead of print].
32. Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer 2013;49(6):1161-8.
33. Licitra L, Mesia R, Rivera F, Remenár E, Hitt R, Erfán J, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2011:2.
34. Rosenthal DI, Harari PM, Giralt J, et al. Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). J Clin Oncol 2014;32(5s) (abstr 6001).
35. http://www.clinicaltrials.gov/ct2/show/NCT01855451.
36. http://www.clinicaltrials.gov/ct2/show/NCT01874171.
37. http://www.clinicaltrials.gov/ct2/show/NCT01302834.